Recent Updates
Recently added Catalysts

Carisma Therapeutics, Inc.

CARMFDA catalysts, PDUFA dates & pipeline intelligence
$0
▲ 0 · 0%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full CARM financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $0.1452W HIGH $1.27
Volume
2.33 K
Value Traded
5.83
Short % Float
0.03%
Days to Cover
1.0
-41.92%Week
-62.82%1 Month
-61.33%3 Month
-19%6 Month
-99.43%5 Year
-99.93%All Time

Cash Data

Unlock CARM cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
6.43 M
EPS (TTM)
-1.18
P/E Ratio
-
Ent. Value
6.13 M
Total Shares
41.79 M
Float Shares
20.40 M
Insiders
49.46%
Institutions
8.10%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every CARM catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

CARM Catalyst Timeline

Dated clinical, regulatory and corporate events for Carisma Therapeutics, Inc.

Unlock the full CARM catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How CARM actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2025-03-31Liver fibrosis development candidate Pre-clinical data readout Pre-clinical
Unlock 1 more CARM historical catalyst
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Showing 1 of 2 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
Vicinium Monoclonal antibodyCompletedNCT02449239Bladder CancerPhase 3 COMPLETED 133May 1, 2022
Unlock the CARM pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every CARM program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
Vicineum High-Grade Non-Muscle-Invasive Bladder CancerPhase 12021-09-103 mo CR rate: 39%; 12 mo CR rate: 17%Read Moreaua2021gurram Sandeep Gurram, Sonia Bellfield, Rebecca Dolan, Beatriz Walter, Maria Merino, Scot Niglio, Andrea Apolo, Piyush Agarwal, Vladimir Valera NCT03258593 @SandeepGurramMD Interim Analysis of a Phase I Single-ArmRead More
Scroll for more · summaries link to the source press release
Unlock every CARM trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock CARM insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Klichinsky MichaelOfficer (Chief Scientific Officer)Option 56,982 56,982 held$0.11 10/07/2025
Unlock the full CARM insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Hedge Funds invested in CARM

Fund % of Portfolio Current MV Shares Owned Activity
No hedge fund reported a 13F position in CARM for Q2 2026.
Unlock every fund holding CARM
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in CARM
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see CARM ownership
Insider and institutional ownership, quarter by quarter.

CARM Short Interest

Shares sold short, counted twice a month.

0.03%
Short % of Float
of tradable shares sold short
6.5K
Shares Sold Short
+0.0% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
7.8K
Avg Daily Volume
the average used for days to cover
Unlock CARM short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock CARM option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live CARM option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock CARM options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How CARM ranks across every disease it competes in

Competitive Position is a premium feature
See how CARM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

CARM News

About Carisma Therapeutics, Inc.

Pa, 19104 carismatx.com
Headquarters3675 Market Street, Suite 200, Philadelphia, PA, 19104, United States
BIOPHARMAWATCH ELITE PLUS
Trade the next CARM catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime